KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Interest Expenses (2017 - 2025)

Regeneron Pharmaceuticals has reported Interest Expenses over the past 16 years, most recently at $12.2 million for Q4 2025.

  • Quarterly results put Interest Expenses at $12.2 million for Q4 2025, up 16.19% from a year ago — trailing twelve months through Dec 2025 was $43.8 million (down 20.65% YoY), and the annual figure for FY2025 was $43.8 million, down 20.65%.
  • Interest Expenses for Q4 2025 was $12.2 million at Regeneron Pharmaceuticals, down from $19.3 million in the prior quarter.
  • Over the last five years, Interest Expenses for REGN hit a ceiling of $19.3 million in Q3 2025 and a floor of $3.6 million in Q2 2025.
  • Median Interest Expenses over the past 5 years was $14.5 million (2021), compared with a mean of $14.4 million.
  • Biggest five-year swings in Interest Expenses: skyrocketed 139.34% in 2021 and later tumbled 75.68% in 2025.
  • Regeneron Pharmaceuticals' Interest Expenses stood at $14.1 million in 2021, then increased by 23.4% to $17.4 million in 2022, then increased by 5.17% to $18.3 million in 2023, then plummeted by 42.62% to $10.5 million in 2024, then grew by 16.19% to $12.2 million in 2025.
  • The last three reported values for Interest Expenses were $12.2 million (Q4 2025), $19.3 million (Q3 2025), and $3.6 million (Q2 2025) per Business Quant data.